Checkpoint Therapeutics Inc (CKPT) has provided an update.
During the Company’s 2024 Annual Meeting, stockholders approved key proposals including the election of seven directors, the ratification of KPMG LLP as the independent auditor, and amendments to increase the authorized common stock by 95 million shares and the incentive plan stock by 12 million shares. Additionally, they voted favorably on executive compensation and its three-year advisory frequency, reflecting active and engaged shareholder participation in the company’s governance and future growth strategy.
For a thorough assessment of CKPT stock, go to TipRanks’ Stock Analysis page.
